Key result
New anticoagulants offer marginal stroke benefit over warfarin in AF while ablation effectively controls rhythm.
Why the study?
Management of atrial fibrillation has evolved with new anticoagulants and procedures, but their benefits and limitations compared to warfarin remain to be clarified.
A review of atrial fibrillation management highlighting the marginal benefits and reversibility issues of new anticoagulants compared to warfarin, and advocating for symptom control via antiarrhythmic drugs and ablation.
May support individualized AF strategies with ablation; leaves open net benefit of new anticoagulants versus warfarin.
The way atrial fibrillation is managed has changed in recent years. Although new anticoagulants are available and more are coming, they offer only marginal benefit over warfarin (Coumadin) and have the disadvantages that their levels cannot be monitored and that their effect cannot be reversed rapidly if bleeding develops. Attempts should be made To Whom It May Concern: control symptomatic atrial fibrillation, first with antiarrhythmic drugs, then with radiofrequency ablation or with a combination. Ablation can be repeated for fibrillation that persists after the first few months.
No takes yet. Share an insight, caveat, or question.
Bruce D. Lindsay (2012) conducted a review in Atrial fibrillation. New anticoagulants, antiarrhythmic drugs, and radiofrequency ablation vs. Standard therapy (e.g., warfarin, traditional antiarrhythmics) was evaluated. New anticoagulants offer marginal benefits over warfarin for stroke prevention in atrial fibrillation, while radiofrequency ablation provides effective rhythm control despite a frequent need for repeat procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: